Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Beginning Cash Balance (2016 - 2025)

Historic Beginning Cash Balance for Summit Therapeutics (SMMT) over the last 3 years, with Q4 2024 value amounting to $75.5 million.

  • Summit Therapeutics' Beginning Cash Balance changed N/A to $75.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $151.0 million, marking a year-over-year increase of 51168.27%. This contributed to the annual value of $100.0 million for FY2024, which is 30508.79% up from last year.
  • Per Summit Therapeutics' latest filing, its Beginning Cash Balance stood at $75.5 million for Q4 2024.
  • Summit Therapeutics' 5-year Beginning Cash Balance high stood at $75.5 million for Q3 2024, and its period low was $24.7 million during Q1 2023.
  • For the 3-year period, Summit Therapeutics' Beginning Cash Balance averaged around $50.2 million, with its median value being $50.2 million (2022).